Brief: Summit Therapeutics Q4 Net Income USD -61.2 Million
24/02/2025 11:05
Feb 24 (Reuters) - Summit Therapeutics Q4 operating expenses USD 65.8 million. * Q4 operating income USD -65.6 million * Q4 EPS USD -0.08
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering